<DOC>
	<DOC>NCT03000348</DOC>
	<brief_summary>This study investigates the use of cysteamine in the treatment of adults with Cystic Fibrosis who are experiencing an exacerbation of CF-associated lung disease. There are six different potential dosing regimens, including one that is placebo.</brief_summary>
	<brief_title>A Study of the Dosing, Efficacy, and Safety of Oral Cysteamine in Adult Patients With Cystic Fibrosis Exacerbations</brief_title>
	<detailed_description>This is a multicenter, double-blind, randomized, placebo-controlled, 6-arm study to investigate the optimal dose regimen, efficacy, and safety of cysteamine in the treatment of adult patients with CF who are experiencing an exacerbation of CF-associated lung disease. Patients will be screened for the study and eligible patients will be randomized to receive either cysteamine or placebo as add-on therapy to their standard of care treatment for CF-associated lung disease.</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Cysteamine</mesh_term>
	<criteria>1. CFassociated lung disease with documented history of chronic infection with Gramnegative organism(s) 2. Established patient of the Principal Investigator's CF Multi Disciplinary Team (MDT) 3. Age ≥18 years 4. Weight &gt;40 kg 5. FEV1 &gt;30% of predicted within the 6 months prior to study exacerbation 6. At the baseline visit: experiencing a new exacerbation of CFassociated lung disease (based on Investigator assessment of ≥4 symptoms present on the Fuchs' criteria) requiring treatment that includes an aminoglycoside antibiotic 7. Women of childbearing potential (not surgically sterile or 2 years postmenopausal) and men with a female partner of childbearing potential must use a medically accepted method of contraception and must agree to continue use of this method for the duration of the study and for 30 days after participation in the study. Acceptable methods of contraception for men and women include abstinence, barrier method (condom or diaphragm) with spermicide, intrauterine device (IUD), vasectomy in conjunction with barrier method, or steroidal contraceptive (oral, transdermal, implanted, injected) in conjunction with a barrier method. 8. Willing and able to comply with all protocol requirements and procedures, including induction of sputum, if necessary 9. Willing and able to provide signed and dated informed consent 1. Hypersensitive to cysteamine or to any of the excipients 2. Hypersensitive to penicillamine 3. Transplant recipient 4. Participation in any other interventional clinical research study (participation in observational studies is not exclusionary) within 30 days of Baseline (Day 0), and any planned participation in an interventional clinical research study for the duration of this study 5. If female, pregnancy, planned pregnancy, or breastfeeding 6. Any other significant disease/disorder which, in the Investigator's opinion, either puts the patient at risk due to study participation, or may influence the results of the study or the patient's ability to participate in the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Exacerbation</keyword>
	<keyword>CF</keyword>
	<keyword>Lung disease</keyword>
	<keyword>Lung infection</keyword>
	<keyword>Gram negative</keyword>
	<keyword>Bacterial Infection</keyword>
	<keyword>pneumonia</keyword>
	<keyword>bronchitis</keyword>
</DOC>